Loading stock data…
VCEL
$37.03+1.26 (+3.52%)
After Hours$37.03+0.00 (+0.00%)· Last close Jun 9
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Vericel Corporation in the Healthcare sector is trading at $37.03 with a market capitalization of $1.7B. Wall Street consensus targets $55.43 (7 analysts), implying a +49.7% move over the next 12 months. The stock is currently 19% below its 52-week high of $45.97, remaining 4.8% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +49.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$37.03
Potential Upside
50.6%
Whystock Fair Value$55.77
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North Ame...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.70B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
77.51
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.16
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
4.66%
Volume
Today's trading volume
617,182
Recent News
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More
Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States.
US High Growth Tech Stocks To Watch
Over the last 7 days, the United States market has risen 1.3% and over the past 12 months, it is up by an impressive 28%, with earnings forecasted to grow by 17% annually. In this robust environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and scalability in line with these positive market trends.
MediWound Q1 Earnings Call Highlights
MediWound (NASDAQ:MDWD) reported a wider first-quarter loss and lower revenue compared with the prior-year period, while management reaffirmed its 2026 revenue outlook and said it continued to advance its EscharEx and NexoBrid programs. On the company’s earnings call, Chief Executive Officer Ofer G
Analysts Have Made A Financial Statement On Vericel Corporation's (NASDAQ:VCEL) First-Quarter Report
A week ago, Vericel Corporation ( NASDAQ:VCEL ) came out with a strong set of first-quarter numbers that could...
Vericel Q1 Earnings Call Highlights
Vericel (NASDAQ:VCEL) reported record first-quarter revenue and raised its full-year 2026 outlook, citing strong growth across its MACI cartilage repair franchise and Burn Care business, as well as expected NexoBrid procurement revenue from a new federal contract. President and Chief Executive Offi